We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4] [5] The company's product portfolio includes prescription medicines and vaccines.
Home | GSK US. GSK delivers third quarter 2024 results. Quarterly results. Behind the science US edition. COiMMUNITY grants provide a ground-level boost to vaccine advocacy. Together we can reduce barriers to adult vaccination. The competitive spirit – getting diversity into the rotation.
GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
Annual Report 2023-24. GSK's 100-year journey in India has drawn inspiration from the passion and commitment of its people. For 100 years your company has earned the trust of generations by consistently delivering high quality medicines and vaccines.
Products. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States. Filter by product area. All product areas. Vaccines. Specialty medicines. General medicines.
Company. At a glance. Getting Ahead Together means preventing disease as well as treating it. Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies. In 2023, US GSK's sales reached $19.6bn.
5 days ago · Get GlaxoSmithKline Pharmaceuticals Ltd (GLAX.NS) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.